Johnson & Johnson Ends Rheumatoid Arthritis Drug Combo Program

Johnson & Johnson (NYSE:JNJ) on Thursday shared topline data from the Phase 2a DAISY proof-of-concept study evaluating the combination of nipocalimab with an anti-tumor necrosis factor alpha (anti-TNFα) therapy in rheumatoid arthritis (RA) patients with refractory disease.

Rheumatoid arthritis (RA) is a long-term autoimmune disorder causing inflammation, pain, and swelling in joints, typically the hands and wrists, and often on both sides of the body.

In 2020, Johnson & Johnson shelled out $6.5 billion to acquire Momenta Pharmaceuticals, gaining access to its lead product, nipocalimab.

Also Read: J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs

At 12 weeks, study results did not show sufficient evidence that ...